口服PCSK9抑制剂恩利西肽治疗成人杂合子型家族性高胆固醇血症的疗效与安全性:一项随机临床试验
这项3期随机临床试验在17个国家59个中心纳入303例杂合子型家族性高胆固醇血症成人患者,随机接受恩利西肽20 mg每日一次(n=202)或安慰剂(n=101)治疗52周。第24周LDL-C平均百分比变化为恩利西肽组-58.2% vs 安慰剂组2.6%(组间差异-59.4%,95%CI -65.6%至-53.2%,P<.001),不良事件发生率两组相似。
要点
- 恩利西肽组第24周LDL-C平均降低58.2%,安慰剂组升高2.6%,组间差异-59.4%(P<.001)。
- 第52周LDL-C平均变化恩利西肽组-55.3% vs 安慰剂组8.7%,组间差异-61.5%(P<.001)。
- 不良事件、严重不良事件及因不良事件停药的发生率两组相似。
核心结论
- 在杂合子型家族性高胆固醇血症成人中,恩利西肽耐受性良好,并显著降低LDL-C、载脂蛋白B、非高密度脂蛋白胆固醇和脂蛋白(a)水平。
研究设计与样本
- 3期随机临床试验,在17个国家59个中心开展,首例受试者于2023年8月8日筛选,末次随访于2025年4月7日。
- 纳入18岁及以上杂合子型家族性高胆固醇血症患者,正在使用降脂治疗(至少中等或高强度他汀),且LDL-C≥55 mg/dL并有主要动脉粥样硬化性心血管疾病史,或LDL-C≥70 mg/dL且无主要动脉粥样硬化性心血管疾病史。
- 参与者按2:1随机分配至恩利西肽20 mg每日一次(n=202)或安慰剂(n=101),治疗52周。
- 共303例随机参与者,平均年龄52.4岁(SD 13.5),51%为女性,293例(96.7%)完成试验。
- 基线平均LDL-C为119.0 mg/dL(SD 41.0 mg/dL),全部正在使用他汀(81.5%使用高强度他汀),64.4%使用依折麦布。
主要发现
- 第24周LDL-C平均百分比变化:恩利西肽组-58.2% vs 安慰剂组2.6%,组间差异-59.4%(95%CI -65.6%至-53.2%,P<.001)。
- 第52周LDL-C平均百分比变化:恩利西肽组-55.3% vs 安慰剂组8.7%,组间差异-61.5%(95%CI -69.4%至-53.7%,P<.001)。
- 第24周非HDL-C平均百分比变化:恩利西肽组-52.3% vs 安慰剂组2.1%,组间差异-53.0%(95%CI -58.5%至-47.4%,P<.001)。
- 第24周载脂蛋白B平均百分比变化:恩利西肽组-48.2% vs 安慰剂组1.8%,组间差异-49.1%(95%CI -54.0%至-44.3%,P<.001)。
- 第24周脂蛋白(a)中位百分比变化:恩利西肽组-24.7% vs 安慰剂组-1.6%,组间差异-27.5%(95%CI -34.3%至-20.6%,P<.001)。
关键数值与推荐
- 主要结局为第24周LDL-C平均百分比变化。
- 次要结局包括第52周LDL-C平均百分比变化、第24周非HDL-C和载脂蛋白B平均百分比变化、第24周脂蛋白(a)中位百分比变化。
- 不良事件、严重不良事件及因不良事件导致的研究中止发生率两组相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Persons with heterozygous familial hypercholesterolemia (HeFH) are at increased risk of atherosclerotic cardiovascular disease due to lifelong elevated levels of low-density lipoprotein cholesterol (LDL-C). Many patients with HeFH do not achieve guideline-recommended LDL-C goals with the currently available lipid-lowering therapies. OBJECTIVE: To evaluate the efficacy of enlicitide decanoate (an oral proprotein convertase subtilisin/kexin type 9 inhibitor) vs placebo in adults with HeFH requiring further lowering of LDL-C levels despite use of statin therapy. DESIGN, SETTING, AND PARTICIPANTS: This phase 3, randomized clinical trial included persons aged 18 years or older with HeFH currently using lipid-lowering therapy (taking at least a moderate- or high-intensity statin) and either an LDL-C level of 55 mg/dL or greater and a history of major atherosclerotic cardiovascular disease or an LDL-C level of 70 mg/dL or greater without a history of major atherosclerotic cardiovascular disease. The trial was conducted at 59 sites across 17 countries; the first participant was screened on August 8, 2023, and the last follow-up visit occurred on April 7, 2025. INTERVENTIONS: Participants were randomized (2:1) to 20 mg of enlicitide (n = 202) or placebo (n = 101) once daily for 52 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was the mean percentage change in LDL-C level at week 24. The secondary outcomes included the mean percentage change in LDL-C level at week 52, the mean percentage change at week 24 in levels of non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B, and the median percentage change at week 24 in lipoprotein(a). RESULTS: Of the 303 participants (mean age, 52.4 [SD, 13.5] years; 51% were female) randomized, 293 (96.7%) completed the trial. The mean LDL-C level was 119.0 mg/dL (SD, 41.0 mg/dL) at baseline, all had statin current use (81.5% were taking a high-intensity statin), and 64.4% were taking ezetimibe. The mean percentage change in LDL-C level at week 24 was -58.2% in the enlicitide group vs 2.6% in the placebo group (between-group difference, -59.4% [95% CI, -65.6% to -53.2%]; P < .001). The mean percentage change in LDL-C level at week 52 was -55.3% in the enlicitide group vs 8.7% in the placebo group (between-group difference, -61.5% [95% CI, -69.4% to -53.7%]; P < .001). At week 24, the mean percentage change in non-HDL-C level was -52.3% in the enlicitide group vs 2.1% in the placebo group (between-group difference, -53.0% [95% CI, -58.5% to -47.4%]; P < .001), the mean percentage change in apolipoprotein B level was -48.2% vs 1.8%, respectively (between-group difference, -49.1% [95% CI, -54.0% to -44.3%]; P < .001), and the median percentage change in lipoprotein(a) level was -24.7% vs -1.6% (between-group difference, -27.5% [95% CI, -34.3% to -20.6%]; P < .001). The incidence of adverse events, serious adverse events, and study discontinuation due to adverse events was similar between groups. CONCLUSIONS: Among adults with HeFH, treatment with enlicitide was well tolerated and significantly reduced levels of LDL-C, apolipoprotein B, non-HDL-C, and lipoprotein(a). TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05952869.
引用
- Ballantyne CM, Gellis L, Tardif JC, et al. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA. 2026. PMID: 41206969. doi:10.1001/jama.2025.20620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。